Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IKT
HOLDInhibikase Therapeutics, Inc. · Healthcare · United States · $366M · Avg Vol: $3M/d
41
StockRankGet insider-trade alerts
Q
36
V
29
M
69
P/E (TTM)
—
ROE
-40.2%
D/E
0.0x
Dividend %
—
Loading 1Y...
PRICE (1Y)+40.7%
SMA 50SMA 200
Close
$2.35
RSI (14)
70.3
52W High
$2.53
From 52W High
0.9%
SCORE BREAKDOWN
Quality
36
ROIC
-32.3%22.9
ROE
-40.2%21.9
GP/Assets
0.6%12.4
Op. Margin
0.0%41.3
FCF/Assets
-15.6%23.5
Piotroski
239.0
Int. Cover
—N/A
D/E Ratio
0.00x97.8
Current Ratio
30.14x97.8
Value
29
P/E (TTM)
—N/A
EV/EBITDA
-4.7x25.0
P/FCF
—N/A
P/B
2.4x53.3
P/S
—N/A
Div Yield
—N/A
Momentum
69
52W High %
93%91.1
RS 6M
27%89.0
SMA 50/200
1.07x77.5
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+14%30.2
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$366M
P/E (Forward)
-6.1x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IKT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IKT | Inhibikase Therapeutics, Inc.(you) | $366M | 41 | HOLD |
| CCCC | C4 Therapeutics, Inc. | $376M | 34 | SELL |
| XFOR | X4 Pharmaceuticals, Inc. | $363M | 33 | SELL |
| OVID | Ovid Therapeutics Inc. | $435M | 34 | SELL |
| CTNM | Contineum Therapeutics, Inc. | $526M | 36 | HOLD |
| AVIR | Atea Pharmaceuticals, Inc. | $379M | 29 | SELL |
| PALI | Palisade Bio, Inc. | $339M | 29 | SELL |
| FENC | Fennec Pharmaceuticals Inc. | $347M | 54 | HOLD |
| OABI | OmniAb, Inc. | $294M | 32 | SELL |
| ELDN | Eledon Pharmaceuticals, Inc. | $276M | 33 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%